IVERIC bio Inc. buy melinda
Start price
03.11.18
/
50%
€2.07
Target price
29.11.18
€2.16
Performance (%)
-21.74%
End price
29.11.18
€1.62
Summary
This prediction ended on 29.11.18 with a price of €1.62. The price of IVERIC bio Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -21.74%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| IVERIC bio Inc. | - | - | - | - |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
Comments by melinda for this prediction
In the thread IVERIC bio Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 26/02 Publication de résultats
Develops novel therapeutics to treat diseases of the eye
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Its product candidates include Zimura and Gene Therapy.
The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Its product candidates include Zimura and Gene Therapy.
The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
Nombre d'employés : 38 personnes.
(Vom Mitglied beendet)